Fufifilm levels mammography patent infringement, anti-trust claims against Hologic

Fujifilm Holdings (TSE:4901) last week accused mammography rival Hologic (NSDQ:HOLX) of patent infringement and unfair trade practices, alleging that Hologic aimed to unlawfully maintain its 80% share in the 3D mammography market. The Japanese tech firm claims in the suit that its Aspire Cristalle system, which sells for roughly half the average $452,000 price of Hologic’s competing Selenia Dimensions system, “has superior image capture technology, delivers lower doses of radiation, and features a patented ‘comfort paddle’ that improves image quality, accuracy of results, and patient comfort.” “As a result of Fujifilm’s threat to Hologic’s monopoly power, Hologic has initiated an anticompetitive scheme to bar Fujifilm from the U.S. market by bringing sham litigation claims against Fujifilm regarding its Aspire Cristalle system, disseminating false and misleading advertising about Hologic’s products to the public, and communicating false and misleading statements about Fujifilm’s Aspire Cristalle system to potential Fujifilm customers,” according to the complaint filed in the U.S. District Court for Delaware. The lawsuit alleges that Marlborough, Mass.-based Hologic’s scheme to dominate the market predates Fujifillm’s 2013 entry into the U.S. 3D mammography market. “Even before Fujifilm’s entry into the U.S. market for 3D mammography, and as part of its anticompetitive scheme, Hologic i...
Source: Mass Device - Category: Medical Devices Authors: Tags: Legal News Mammography Patent Infringement fujifilm Hologic Source Type: news